Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans

Drug Safety

Volumn 29, Issue 3, 2006, Pages 237-254

  Aubert, Marion ^a   Osterwalder, Rolf ^b   Wagner, Bj̈orn ^b   Parrilla, Isabelle ^b   Cavero, Icilio ^c   Doessegger, Lucette ^a   Ertel, Eric A ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMLODIPINE; AMOXICILLIN; ASTEMIZOLE; BEPRIDIL; CAPTOPRIL; CISAPRIDE; CLEMASTINE; DOFETILIDE; ERYTHROMYCIN; FLUOXETINE; HALOPERIDOL; IBUPROFEN; ISRADIPINE; NIFEDIPINE DERIVATIVE; NORFLOXACIN; PIMOZIDE; PROBUCOL; QUINIDINE; SIMVASTATIN; SOTALOL; SPARFLOXACIN; TAMOXIFEN; TERFENADINE; THIORIDAZINE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; IN VITRO STUDY; MATHEMATICAL COMPUTING; NONHUMAN; PRIORITY JOURNAL; PURKINJE FIBER; QT PROLONGATION; RABBIT; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR AGENTS; DRUG EVALUATION, PRECLINICAL; FEMALE; HEART; HISTAMINE H1 ANTAGONISTS; HUMANS; LONG QT SYNDROME; PREDICTIVE VALUE OF TESTS; PURKINJE FIBERS; RABBITS; RISK; TORSADES DE POINTES;

EID: 33644844112     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629030-00007     Document Type: Article

References (47)

1. Brochier M, Fauchier JP. Torsades de pointe et rentŕees provoqúees par les antiarhytmiques. Arch Mal Coeur Vaiss 1978; 71 (4): 477-88
2. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350 (10): 1013-22
3. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58 (1): 32-45
4. European Medicines Evaluation Agency. Committee for Proprietary Medicinal Products. 'Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal produts' (CPMP/986/96) [online]. Available from URL: http://www.emea.eu.int/pdfs/human/swp/098696en.pdf [Accessed 2006 Feb 10]
5. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10 (6): 483-6
6. Adamantidis MM, Kerram P, Dupuis BA. In vitro electrophysiological detection of iatrogenic arrhythmogenicity. Fundam Clin Pharmacol 1994; 8 (5): 391-407
7. Abrahamsson C, Duker G, Lundberg C, et al. Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031. Cardiovasc Res 1993; 27 (5): 861-7
8. De Cicco M, Macor F, Robieux I, et al. Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unit. Crit Care Med 1999; 27 (2): 332-9
9. Peters FP, de Zwaan C, Kho L. Prolonged QT interval and ventricular fibrillation after treatment with sublingual nifedipine for malignant hypertension. Arch Intern Med 1997; 157 (22): 2665-6
10. Grayson HA, Kennedy JD. Torsades de pointes and nifedipine [letter]. Ann Intern Med 1982; 97 (1): 144
11. Lherm T, Lottin F, Larbi D, et al. Torsade de pointes after poisoning with fluoxetine alone [in French]. Presse Med 2000; 29 (6): 306-7
12. Varriale P. Fluoxetine (Prozac) as a cause of QT prolongation [letter]. Arch Intern Med 2001; 161 (4): 612
13. Manna PK, Basu SK. Studies of erythromycin maltobionate, a new derivative of erythromycin. Drug Dev Ind Pharm 1999; 25 (3): 391-5
14. De Bruin ML, Pettersson M, Meyboom RH, et al. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 2005; Mar; 26 (6): 590-7
15. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001; 103 (15): 2004-13
16. Grant AO, Whalley DW, Wendt DJ. Pharmacology of the cardiac sodium channel. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. Philadelphia (PA): WB Saunders Co, 1995: 247-59
17. Nishimura M, Follmer CH, Singer DH. Amiodarone blocks calcium current in single guinea pig ventricular myocytes. J Pharmacol Exp Ther 1989; 251 (2): 650-9
18. Wang YG, Lu ZY. Effect of captopril on membrane currents of ventricular myocytes. J Tongji Med Univ 1995; 15 (4): 209-11
19. Miyazaki H, Matsunaga Y, Nambu K, et al. Disposition and metabolism of [14C]-haloperidol in rats. Arzneimittel Forschung 1986; 36 (3): 443-52
20. Leeson GA, Chan KY, Knapp WC, et al. Metabolic disposition of terfenadine in laboratory animals. Arzneimittel Forschung 1982; 32 (9a): 1173-8
21. Pang DC, Sperelakis N. Nifedipine, diltiazem, bepridil and verapamil uptakes into cardiac and smooth muscles. Eur J Pharmacol 1983; 87 (2-3): 199-207
22. Bandyopadhyay S, Somani P. A comparison of plasma, white blood cell, red blood cell, and tissue distribution of amiodarone and desethylamiodarone in anesthetized dogs. J Cardiovasc Pharmacol 1987; 10 (4): 379-88
23. Michiels M, Van-Peer A, Woestenborghs R, et al. Pharmacokinetics and tissue distribution of astemizole in the dog. Drug Dev Res 1986; 8 (1-4): 53-62
24. DRUGDEX® system. Thomson Micromedex, Greenwood Village (CO)
25. Desta Z, Kivisto KT, Lilja JJ, et al. Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. Br J Clin Pharmacol 2001; 52: 399-407
26. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24 (1): 62-9
27. Nyberg G, Axelsson R, Martensson E. Binding of thioridazine and thioridazine metabolites to serum proteins in psychiatric patients. Eur J Clin Pharmacol 1978; 14 (5): 341-50
28. Hamelin BA, Turgeon J, Vallee F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996; 60 (5): 512-21
29. Lebeau JE. Animal toxicity studies of probucol (author's translation) [in French]. Nouv Presse Med 1980; 9 (40): 3001-4
30. Rials SJ, Wu Y, Xu X, et al. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. Circulation 1997; 96 (4): 1330-6
31. Chiladakis JA, Karapanos G, Agelopoulos G, et al. Effects of early captopril therapy after myocardial infarction on the incidence of late potentials. Clin Cardiol 2000; 23 (2): 96-102
32. Budaj A, Cybulski J, Cedro K, et al. Effects of captopril on ventricular arrhythmias in the early and late phase of suspected acute myocardial infarction: randomized, placebo-controlled substudy of ISIS-4. Eur Heart J 1996; 17 (10): 1506-10
33. Witchel HJ, Pabbathi VK, Hofmann G, et al. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett 2002; 512 (1-3): 59-66
34. Zhang S, Zhou Z, Gong Q, et al. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 1999; 84 (9): 989-98
35. Pacher P, Magyar J, Szigligeti P, et al. Electrophysiological effects of fluoxetine in mammalian cardiac tissues. Naunyn Schmiedebergs Arch Pharmacol 2000; 361 (1): 67-73
36. Noguchi K, Masumiya H, Takahashi K, et al. Comparative effects of gallopamil and verapamil on the mechanical and electrophysiological parameters of isolated guinea-pig myocardium. Can J Physiol Pharmacol 1997; 75 (12): 1316-21
37. Pancrazio JJ, Kamatchi GL, Roscoe AK, et al. Inhibition of neuronal Na+ channels by antidepressant drugs. J Pharmacol Exp Ther 1998; 284 (1): 208-14
38. Grima M, Freyss-Beguin M, Millanvoye-Van Brussel E, et al. Effects of various antianginal drugs on sodium influx in rat brain synaptosomes and in rat heart muscle cells in culture. Eur J Pharmacol 1987; 138 (1): 1-8
39. Yatani A, Brown AM, Schwartz A. Bepridil block of cardiac calcium and sodium channels. J Pharmacol Exp Ther 1986; 237 (1): 9-17
40. Enyeart JJ, Dirksen RT, Sharma VK, et al. Antipsychotic pimozide is a potent Ca2+ channel blocker in heart. Mol Pharmacol 1990; 37 (5): 752-7
41. Liu S, Melchert RB, Kennedy RH. Inhibition of L-type Ca2+ channel current in rat ventricular myocytes by terfenadine. Circ Res 1997; 81 (2): 202-10
42. Champeroux P, Viaud K, El Amrani Al, et al. Prediction of the risk of torsade de pointes using the model of isolated canine Purkinje fibres. Br J Pharmacol 2005 Feb; 144 (3): 376-85
43. de Buitleir M, Rowland E, Krikler DM. Hemodynamic effects of nifedipine given alone and in combination with atenolol in patients with impaired left ventricular function. Am J Cardiol 1985; 55 (12): 15-20E
44. Pham TV, Rosen MR. Sex, hormones, and repolarization. Cardiovasc Res 2002; 53 (3): 740-51
45. Liu XK, Katchman A, Drici MD, et al. Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J Pharmacol Exp Ther 1998; 285 (2): 672-9
46. Lu HR, Marien R, Saels A, et al. Species plays an important role in drug-induced prolongation of action potential duration and early after depolarizations in isolated Purkinje fibers. J Cardiovasc Electrophysiol 2001; 12 (1): 93-102
47. Gintant GA, Limberis JT, McDermott JS, et al. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol 2001; 37 (5): 607-18